Avanir Targets Watson In Suit Over Nuedexta Patents
Avanir claims that New Jersey-based Watson's planned generic version of the drug — which is sold in capsule form and used to treat involuntary laughing and crying disorders in patients with underlying brain conditions — infringed two of its patents.
The California-based company contends it would...
Already a subscriber? Click here to login